trending Market Intelligence /marketintelligence/en/news-insights/trending/xtt3hgd10mmqjbcdf7fxqw2 content esgSubNav
In This List

Bavarian Nordic, Defense Department to develop vaccine for mosquito-borne virus

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Bavarian Nordic, Defense Department to develop vaccine for mosquito-borne virus

Denmark's Bavarian Nordic A/S entered into a collaboration with the U.S. Department of Defense to develop a vaccine for equine encephalitis virus, a rare but potentially deadly mosquito-borne illness.

The agreement includes total potential payments of about $36 million.

The biotechnology company will use its Modified Vaccinia Ankara - Bavarian Nordic, or MVA-BN platform, to develop a vaccine against various strains of the virus, for which there is currently no preventative vaccine treatment available.

A candidate vaccine based on the platform has already shown efficacy in preclinical models targeting Eastern, Venezuelan and Western equine encephalitis viruses.

The multiyear collaboration will include further preclinical studies to support clinical development, production, and establishment of safety and immunogenicity in humans.